Economic and Clinical Burden of Opioid-Induced Nausea and Vomiting.
Publication/Presentation Date
1-1-2017
Abstract
Opioids are the standard of care for treating moderate-to-severe pain; however, their efficacy can be limited by adverse events (AEs), including nausea and vomiting. Opioid-induced nausea and vomiting (OINV) is an inherent adverse effect of opioid treatment, exerting effects centrally and peripherally. Opioid-related AEs can impact treatment adherence and discontinuation, which can result in inadequate pain management. OINV may persist long-term, negatively affecting patient functional outcomes, physical and mental health, patient satisfaction, and overall costs of treatment. Multiple factors may contribute to OINV, including activation of opioid receptors in the chemoreceptor trigger zone, vestibular apparatus, and gastrointestinal tract. Prophylactic or early treatment with antiemetics may be appropriate for patients who are at high risk for OINV.
Volume
129
Issue
1
First Page
111
Last Page
117
ISSN
1941-9260
Published In/Presented At
Nicholson, B. D. (2017). Economic and clinical burden of opioid-induced nausea and vomiting. Postgraduate Medicine, 129(1), 111-117. doi:10.1080/00325481.2017.1243004
Disciplines
Anesthesiology | Medical Sciences | Medicine and Health Sciences
PubMedID
27690715
Department(s)
Department of Medicine, Department of Medicine Faculty, Department of Anesthesiology
Document Type
Article